Document is current

Article History

Received: 17 November 2020

Accepted: 26 April 2021

First Online: 26 May 2021

Declarations

:

: This survey was conducted among physicians and no data on patients are presented.

: Not applicable.

: A. Redondo reports honoraria and advisory/consultancy (MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar, Lilly, Amgen), research grant/funding to his institution (Eisai, PharmaMar, Roche), travel/accommodation/expenses (AstraZeneca, Tesaro, PharmaMar, Roche), and speakers bureau (MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar), outside the submitted work.A. Oaknin has served on advisory boards for Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro, Inmunogen and Genmab and received support for travel or accommodation from Roche, AstraZeneca, and PharmaMar; she also reports payments to the institution from Abbvie Deutschland, Abililty Pharmaceuticals, Advaxis Inc., Aeterna Zentaris, AMGEM, SA, Aprea Therapeutics AB, Clovis Oncology Inc., EISAI limited LTD, F. Hoffmann – La Roche LTD, Regeneron Pharmaceuticals, Immunogen Inc., Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc., Pharma Mar SA, Tesaro Inc., BMS, Bristrol Meyers Squibb.M.J. Rubio has served on advisory boards for MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar and received support for travel or accommodation from Roche, AstraZeneca, and PharmaMar.M-P. Barretina-Ginesta has served on Advisory boards for Roche, AstraZeneca, PharmaMar, Clovis Oncology, GSK, Merck Sharp & Dohme; has received speaker bureau honoraria from AstraZeneca, Roche, PharmaMar, GSK, Clovis Oncology and received support for travel or accommodation from Roche, AstraZeneca, GSK and PharmaMar.A. de Juan reports personal fees and other from Roche, AstraZeneca, Pharma Mar, Clovis Oncology, Tesaro, Eisai Ltd., Pierre-Fabre and Pfizer, outside the submitted work.L. Manso has received advisory/consultancy honorarium from AstraZeneca, Clovis Oncology, Genmab, GSK, Merck Sharp & Dohme, Novartis, Pfizer/Merck, PharmaMar, Roche; has received speaker bureau/expert testimony honorarium from AstraZeneca, PharmaMar, Roche, GSK, Roche; has received research grant/funding from TESARO: A GSK Company; and has received travel/accommodation/expenses from AstraZeneca, Novartis, Roche, TESARO: A GSK Company.I. Romero has received speaker’s bureau honorarium from AstraZeneca, Pharmamar, GSK, Clovis, Roche; has received advisory board honorarium from AstraZeneca, GSK, Clovis, Roche; has received travel/expenses from AstraZeneca, Pharmamar, GSK, Roche; and has received research grant/funding from Roche, GSK.C. Martin-Lorente reports honoraria and advisory/consultancy (AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar, Roche); travel/accommodation/expenses (AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar, Roche); and speakers bureau (AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar, Roche).A. Poveda has had a consulting or advisory role for AstraZeneca, PharmaMar, Roche, Clovis Oncology, and Tesaro; and has received travel/accommodations/expenses from PharmaMar.A. Gonzalez-Martín has received advisory/consultancy honorarium from Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, Novartis, Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio; has received speaker bureau/expert testimony honorarium from AstraZeneca, PharmaMar, Roche, GSK; has received research grant/funding from Roche, TESARO: A GSK Company; and has received travel/accommodation/expenses from AstraZeneca, Pharmamar, Roche, TESARO: A GSK Company.